Background: Acute upper gastrointestinal bleeding (UGIB) is very critical medical disorder related through significant morbidity and death. While various treatment modalities exist, there is a growing interest in exploring adjunctive therapies to improve outcomes. Tranexamic acid (TXA) has been planned as a potential adjunctive therapy due to its ability to reduce bleeding in other clinical settings. The current research aims to investigate effectiveness and safety of TXA when used as an adjunctive therapy in managing acute UGIB.